Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Related MRK
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Markets Marginally Lower Ahead Of Earnings Season
Stocks Poised to Slip from Record Highs (Fox Business)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free